Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» ImmunoGen, Inc. Announces Clinical Data for T-DM1 Used in Combination with Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer
ImmunoGen, Inc. Announces Clinical Data for T-DM1 Used in Combination with Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer
ImmunoGen, Inc. Announces Clinical Data for T-DM1 Used in Combination with Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer
Submitted by
admin
on December 11, 2010 - 11:48am
Source:
Yahoo/BusinessWire
News Tags:
Immunogen
T-DM1
Pertuzumab
breast cancer
HER2 Inhibitor
trastuzumab
Headline:
ImmunoGen, Inc. Announces Clinical Data for T-DM1 Used in Combination with Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer
Do Not Allow Advertisers to Use My Personal information
